AANP SmartBrief Latest Industry Press Releases

The Board of Directors of Invacare Corporation (NYSE:IVC) announced that it declared a cash dividend of $.0125 per share on its common shares and $.011364 per share on its Class B common shares payable January 14, 2010 to shareholders of record on January 5, 2010.... (more)

University of Colorado Hospital (UCH) Adopts TandemHeart Versatile Circulatory Support Device from CardiacAssist

Business Wire | 3 days 13 hours 43 minutes ago

CardiacAssist Inc. announced today that the University of Colorado Hospital (UCH) has adopted the company’s TandemHeart® System.... (more)

Impax Laboratories Drives Stronger Performance with IBM Business Analytics

PRNewswire | 3 days 14 hours 31 minutes ago

ARMONK, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- IBM ... (more)

Discus Dental Announces Redesigned Zoom Chairside Whitening Kit

MarketWire | 3 days 14 hours 31 minutes ago

CULVER CITY, CA -- (Marketwire) -- 11/20/09 -- Discus Dental®, LLC today announced the release of its newly redesigned Zoom® Chairside Whitening Kit, improving overall procedure ease of use and safety by reducing the total number of steps in the Zoom procedure. ... (more)

POZEN Announces Start of Enrollment For PA32540 Phase 3 Program

Business Wire | 3 days 15 hours ago

POZEN Inc. (NASDAQ: POZN) announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.... (more)

FDA Approves Intravenous Formulation Of Pfizer s Revatio (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

Business Wire | 3 days 15 hours 1 minute ago

Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.... (more)

European CHMP Formally Adopts Negative Opinion on Oncophage

Business Wire | 3 days 15 hours 1 minute ago

Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer). A negative vote of the CHMP indicating this opinion was verbally conveyed to Antigenics and announced in a press release issu...... (more)

Dendreon Receives FDA Acknowledgement of Complete Response

PRNewswire | 3 days 15 hours 1 minute ago

... (more)

Quest Diagnostics Announces Final Tender Offer Results

PRNewswire | 3 days 15 hours 1 minute ago

... (more)

< Prev 1 2 3 4 5 Next >

65 Press Releases | RSS Feed

Sign up for AANP SmartBrief

Designed specifically for nurse practitioners and health care professionals like you, AANP SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important health care issues. Learn more

Subscribe to the AANP SmartBrief RSS feed

Publish your Press Release

Latest Blog Postsview more

Tales of the Grim Reaper from Montreal
Health business blog

Are Your Kids Active Enough?
Diet-Blog

Public Anxiety Meets The Democratic Effort to Get Health Care Done at All Costs
Health Care Blog, The

Grasping the Third Rail
Stayin' Alive

Press Releases

Sign up for AANP SmartBrief

Latest Blog Postsview more

Companies in the news